Michael Cherny
Stock Analyst at B of A Securities
(3.95)
# 621
Out of 4,996 analysts
118
Total ratings
54.44%
Success rate
10.39%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Outperform | $785 → $850 | $760.55 | +11.76% | 15 | Sep 24, 2025 | |
| PINC Premier | Maintains: Underperform | $19 → $21 | $27.81 | -24.49% | 10 | Aug 19, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $153.71 | +21.01% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $21.46 | +30.48% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.14 | +163.16% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $20.35 | +13.02% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $496.79 | -33.57% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $58.40 | -31.51% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $75.77 | -1.02% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $74.40 | +20.97% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $126.19 | +121.89% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $135 → $174 | $188.99 | -7.93% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $66.04 | +27.20% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $179.56 | +38.12% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $163.79 | +55.69% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.50 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $307.00 | -10.42% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $280.61 | -7.34% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.04 | +98.02% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.80 | +61.02% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $8.16 | +108.33% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $4.53 | +1,058.94% | 2 | Jan 5, 2022 |
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $760.55
Upside: +11.76%
Premier
Aug 19, 2025
Maintains: Underperform
Price Target: $19 → $21
Current: $27.81
Upside: -24.49%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $153.71
Upside: +21.01%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $21.46
Upside: +30.48%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.14
Upside: +163.16%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $20.35
Upside: +13.02%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $496.79
Upside: -33.57%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $58.40
Upside: -31.51%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $75.77
Upside: -1.02%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $74.40
Upside: +20.97%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $126.19
Upside: +121.89%
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $188.99
Upside: -7.93%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $66.04
Upside: +27.20%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $179.56
Upside: +38.12%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $163.79
Upside: +55.69%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.50
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $307.00
Upside: -10.42%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $280.61
Upside: -7.34%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.04
Upside: +98.02%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.80
Upside: +61.02%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $8.16
Upside: +108.33%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $4.53
Upside: +1,058.94%